company background image
2269

WuXi Biologics (Cayman) SEHK:2269 Stock Report

Last Price

HK$48.30

Market Cap

HK$206.0b

7D

0.7%

1Y

-58.2%

Updated

03 Oct, 2022

Data

Company Financials +
2269 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance3/6
Financial Health6/6
Dividends0/6

2269 Stock Overview

WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development and manufacturing in the People’s Republic of China, North America, Europe, and internationally.

WuXi Biologics (Cayman) Competitors

Price History & Performance

Summary of all time highs, changes and price drops for WuXi Biologics (Cayman)
Historical stock prices
Current Share PriceHK$48.30
52 Week HighHK$124.80
52 Week LowHK$40.30
Beta0.89
1 Month Change-27.31%
3 Month Change-41.53%
1 Year Change-58.22%
3 Year Change81.24%
5 Year Change266.84%
Change since IPO412.92%

Recent News & Updates

Sep 08
WuXi Biologics (Cayman) (HKG:2269) Seems To Use Debt Quite Sensibly

WuXi Biologics (Cayman) (HKG:2269) Seems To Use Debt Quite Sensibly

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Shareholder Returns

2269HK Life SciencesHK Market
7D0.7%1.4%-4.4%
1Y-58.2%-61.5%-28.8%

Return vs Industry: 2269 exceeded the Hong Kong Life Sciences industry which returned -61.5% over the past year.

Return vs Market: 2269 underperformed the Hong Kong Market which returned -28.8% over the past year.

Price Volatility

Is 2269's price volatile compared to industry and market?
2269 volatility
2269 Average Weekly Movement9.0%
Life Sciences Industry Average Movement7.0%
Market Average Movement6.5%
10% most volatile stocks in HK Market12.7%
10% least volatile stocks in HK Market3.1%

Stable Share Price: 2269 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: 2269's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201410,593Chris Chenhttps://www.wuxibiologics.com

WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development and manufacturing in the People’s Republic of China, North America, Europe, and internationally. The company also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sale of medicals; vaccine CDMO and related business; and material supplier activities. WuXi Biologics (Cayman) Inc. has strategic partnership with ImmuneOncia Therapeutics, Legochem Biosciences Inc, Worg Pharma, OncoC4, and Exelixis Inc. The company was incorporated in 2014 and is headquartered in Wuxi, China.

WuXi Biologics (Cayman) Fundamentals Summary

How do WuXi Biologics (Cayman)'s earnings and revenue compare to its market cap?
2269 fundamental statistics
Market CapHK$206.04b
Earnings (TTM)HK$4.50b
Revenue (TTM)HK$14.44b

45.8x

P/E Ratio

14.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
2269 income statement (TTM)
RevenueCN¥13.09b
Cost of RevenueCN¥7.14b
Gross ProfitCN¥5.95b
Other ExpensesCN¥1.86b
EarningsCN¥4.08b

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.96
Gross Margin45.42%
Net Profit Margin31.18%
Debt/Equity Ratio8.1%

How did 2269 perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is 2269 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 2269?

Other financial metrics that can be useful for relative valuation.

2269 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue13.9x
Enterprise Value/EBITDA39.6x
PEG Ratio1.9x

Price to Earnings Ratio vs Peers

How does 2269's PE Ratio compare to its peers?

2269 PE Ratio vs Peers
The above table shows the PE ratio for 2269 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average16.3x
1521 Frontage Holdings
24.1x28.1%HK$4.3b
1873 Viva Biotech Holdings
19.6x61.1%HK$2.4b
6118 Austar Lifesciences
6.2xn/aHK$722.7m
1093 CSPC Pharmaceutical Group
15.3x11.6%HK$92.9b
2269 WuXi Biologics (Cayman)
45.8x23.6%HK$206.0b

Price-To-Earnings vs Peers: 2269 is expensive based on its Price-To-Earnings Ratio (45.8x) compared to the peer average (16.3x).


Price to Earnings Ratio vs Industry

How does 2269's PE Ratio compare vs other companies in the Asian Life Sciences Industry?

Price-To-Earnings vs Industry: 2269 is expensive based on its Price-To-Earnings Ratio (45.8x) compared to the Asian Life Sciences industry average (34.6x)


Price to Earnings Ratio vs Fair Ratio

What is 2269's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

2269 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio45.8x
Fair PE Ratio24.5x

Price-To-Earnings vs Fair Ratio: 2269 is expensive based on its Price-To-Earnings Ratio (45.8x) compared to the estimated Fair Price-To-Earnings Ratio (24.5x).


Share Price vs Fair Value

What is the Fair Price of 2269 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 2269 (HK$48.3) is trading below our estimate of fair value (HK$86.65)

Significantly Below Fair Value: 2269 is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Future Growth

How is WuXi Biologics (Cayman) forecast to perform in the next 1 to 3 years based on estimates from 28 analysts?

Future Growth Score

5/6

Future Growth Score 5/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


23.6%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 2269's forecast earnings growth (23.6% per year) is above the savings rate (1.6%).

Earnings vs Market: 2269's earnings (23.6% per year) are forecast to grow faster than the Hong Kong market (16.8% per year).

High Growth Earnings: 2269's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 2269's revenue (24% per year) is forecast to grow faster than the Hong Kong market (9.7% per year).

High Growth Revenue: 2269's revenue (24% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 2269's Return on Equity is forecast to be low in 3 years time (16.2%).


Discover growth companies

Past Performance

How has WuXi Biologics (Cayman) performed over the past 5 years?

Past Performance Score

3/6

Past Performance Score 3/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


51.6%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 2269 has high quality earnings.

Growing Profit Margin: 2269's current net profit margins (31.2%) are lower than last year (34.6%).


Past Earnings Growth Analysis

Earnings Trend: 2269's earnings have grown significantly by 51.6% per year over the past 5 years.

Accelerating Growth: 2269's earnings growth over the past year (46%) is below its 5-year average (51.6% per year).

Earnings vs Industry: 2269 earnings growth over the past year (46%) exceeded the Life Sciences industry -51.3%.


Return on Equity

High ROE: 2269's Return on Equity (12%) is considered low.


Discover strong past performing companies

Financial Health

How is WuXi Biologics (Cayman)'s financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: 2269's short term assets (CN¥20.7B) exceed its short term liabilities (CN¥9.0B).

Long Term Liabilities: 2269's short term assets (CN¥20.7B) exceed its long term liabilities (CN¥3.0B).


Debt to Equity History and Analysis

Debt Level: 2269 has more cash than its total debt.

Reducing Debt: 2269's debt to equity ratio has reduced from 31.2% to 8.1% over the past 5 years.

Debt Coverage: 2269's debt is well covered by operating cash flow (142.1%).

Interest Coverage: 2269 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Dividend

What is WuXi Biologics (Cayman) current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage


0.11%

Forecast Dividend Yield

Dividend Yield vs Market

WuXi Biologics (Cayman) Dividend Yield vs Market
How does WuXi Biologics (Cayman) dividend yield compare to the market?
SegmentDividend Yield
Company (WuXi Biologics (Cayman))n/a
Market Bottom 25% (HK)3.0%
Market Top 25% (HK)9.0%
Industry Average (Life Sciences)0.7%
Analyst forecast in 3 Years (WuXi Biologics (Cayman))0.1%

Notable Dividend: Unable to evaluate 2269's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 2269's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 2269's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 2269's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 2269 has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.4yrs

Average management tenure


CEO

Chris Chen (49 yo)

8.67yrs

Tenure

CN¥50,794,000

Compensation

Dr. Zhisheng Chen, also known as Chris, has been the Chief Executive Officer & Executive Director at WuXi Biologics (Cayman) Inc. since January 01, 2016 and since February 27, 2014 respectively. Dr. Chen i...


CEO Compensation Analysis

Chris Chen's Compensation vs WuXi Biologics (Cayman) Earnings
How has Chris Chen's remuneration changed compared to WuXi Biologics (Cayman)'s earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a

CN¥4b

Mar 31 2022n/an/a

CN¥4b

Dec 31 2021CN¥51mCN¥3m

CN¥3b

Sep 30 2021n/an/a

CN¥3b

Jun 30 2021n/an/a

CN¥3b

Mar 31 2021n/an/a

CN¥2b

Dec 31 2020CN¥31mCN¥3m

CN¥2b

Sep 30 2020n/an/a

CN¥1b

Jun 30 2020n/an/a

CN¥1b

Mar 31 2020n/an/a

CN¥1b

Dec 31 2019CN¥25mCN¥3m

CN¥1b

Sep 30 2019n/an/a

CN¥922m

Jun 30 2019n/an/a

CN¥831m

Mar 31 2019n/an/a

CN¥731m

Dec 31 2018CN¥20mCN¥2m

CN¥631m

Sep 30 2018n/an/a

CN¥520m

Jun 30 2018n/an/a

CN¥410m

Mar 31 2018n/an/a

CN¥331m

Dec 31 2017CN¥24mCN¥2m

CN¥253m

Sep 30 2017n/an/a

CN¥177m

Jun 30 2017n/an/a

CN¥149m

Mar 31 2017n/an/a

CN¥145m

Dec 31 2016CN¥22mCN¥2m

CN¥141m

Sep 30 2016n/an/a

CN¥171m

Dec 31 2015CN¥9mCN¥2m

CN¥45m

Compensation vs Market: Chris's total compensation ($USD7.14M) is above average for companies of similar size in the Hong Kong market ($USD935.09K).

Compensation vs Earnings: Chris's compensation has increased by more than 20% in the past year.


Leadership Team

Experienced Management: 2269's management team is considered experienced (3.4 years average tenure).


Board Members

Experienced Board: 2269's board of directors are considered experienced (5.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

SEHK:2269 Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
15 Sep 22SellHK$5,526,404,474J.P. Morgan Asset Management, Inc.Company101,886,115HK$54.24
13 Sep 22BuyHK$518,244,839J.P. Morgan Asset Management, Inc.Company9,361,207HK$55.36
22 Aug 22SellHK$56,163,153BlackRock, Inc.Company797,000HK$70.47
21 Jul 22BuyHK$42,290,822J.P. Morgan Asset Management, Inc.Company521,000HK$81.17
21 Jul 22BuyHK$4,618,710JPMorgan Chase & Co, Private Banking and Investment Banking InvestmentsCompany56,900HK$81.17
21 Jul 22SellHK$405,862J.P. Morgan Asset Management, Inc.Company5,000HK$81.17
21 Jul 22SellHK$711,610,947JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany8,766,661HK$81.17
20 Jul 22BuyHK$266,693,312J.P. Morgan Asset Management, Inc.Company3,304,709HK$80.70
07 Jul 22BuyHK$48,895,494J.P. Morgan Asset Management, Inc.Company595,000HK$82.18
07 Jul 22SellHK$1,191,571J.P. Morgan Asset Management, Inc.Company14,500HK$82.18
07 Jul 22SellHK$4,437,574JPMorgan Chase & Co, Private Banking and Investment Banking InvestmentsCompany54,000HK$82.18
07 Jul 22SellHK$542,021,504JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany6,595,757HK$82.18
06 Jul 22BuyHK$344,628,164J.P. Morgan Asset Management, Inc.Company4,135,485HK$83.33
22 Jun 22BuyHK$543William Robert KellerIndividual8HK$67.90
22 Jun 22BuyHK$543Teh Ming KwaukIndividual8HK$67.90
22 Jun 22BuyHK$543Kenneth Walton HitchnerIndividual8HK$67.90
15 Jun 22SellHK$2,546,374Weichang ZhouIndividual38,912HK$65.44
15 Jun 22SellHK$17,074,552Zhisheng ChenIndividual260,922HK$65.44
10 Jun 22SellHK$104,167,046Ge Li And Ning Zhao Family Foundation, Endowment ArmCompany1,500,000HK$69.44
09 Jun 22BuyHK$701,577,062Capital Research and Management CompanyCompany9,906,482HK$70.82
08 Jun 22SellHK$294,684,618Ge Li And Ning Zhao Family Foundation, Endowment ArmCompany4,745,500HK$62.10
01 Jun 22SellHK$92,472,609Capital Research and Management CompanyCompany1,623,922HK$56.94
17 May 22BuyHK$68,343,369JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany1,267,545HK$53.92
17 May 22SellHK$13,587,312J.P. Morgan Asset Management, Inc.Company252,000HK$53.92
17 May 22SellHK$374,278,784JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany6,941,642HK$53.92
16 May 22BuyHK$427,952,555J.P. Morgan Asset Management, Inc.Company8,077,335HK$52.98
06 May 22SellHK$395,640,316J.P. Morgan Asset Management, Inc.Company7,763,362HK$50.96
05 May 22BuyHK$304,138,400J.P. Morgan Asset Management, Inc.Company5,626,535HK$54.05
28 Mar 22SellHK$410,191,157J.P. Morgan Asset Management, Inc.Company6,268,480HK$65.44
24 Mar 22BuyHK$260,439,648JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany3,782,244HK$68.86
24 Mar 22BuyHK$112,928JPMorgan Chase & Co, Private Banking and Investment Banking InvestmentsCompany1,640HK$68.86
24 Mar 22BuyHK$871,473J.P. Morgan Asset Management, Inc.Company12,656HK$68.86
24 Mar 22SellHK$3,787,217JPMorgan Chase & Co, Private Banking and Investment Banking InvestmentsCompany55,000HK$68.86
24 Mar 22SellHK$18,592J.P. Morgan Asset Management, Inc.Company270HK$68.86
23 Mar 22SellHK$90,335,121J.P. Morgan Asset Management, Inc.Company1,401,068HK$64.48
22 Mar 22SellHK$53,998,220BlackRock, Inc.Company979,238HK$55.14
17 Mar 22BuyHK$91,023,583BlackRock, Inc.Company1,647,775HK$55.24
16 Mar 22BuyHK$84,605,626Capital Research and Management CompanyCompany1,880,292HK$45.00
15 Mar 22BuyHK$157,710,348J.P. Morgan Asset Management, Inc.Company3,674,373HK$42.92
15 Feb 22SellHK$436,044,874Capital Research and Management CompanyCompany7,182,068HK$60.71
11 Feb 22BuyHK$310,459,971Capital Research and Management CompanyCompany5,536,316HK$56.08
07 Feb 22SellHK$160,295,655J.P. Morgan Asset Management, Inc.Company1,978,502HK$81.02
31 Jan 22BuyHK$8,645,814,151J.P. Morgan Asset Management, Inc.Company113,800,698HK$75.97
11 Jan 22BuyHK$17,829,146Zhisheng ChenIndividual202,000HK$88.26
07 Jan 22BuyHK$13,316,868,023J.P. Morgan Asset Management, Inc.Company165,443,586HK$80.49
07 Jan 22BuyHK$42,307,668JPMorgan Chase & Co, Private Banking and Investment Banking InvestmentsCompany525,614HK$80.49
07 Jan 22BuyHK$1,855,681,032JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany23,054,259HK$80.49
07 Jan 22SellHK$6,917,916,302J.P. Morgan Asset Management, Inc.Company85,945,500HK$80.49
07 Jan 22SellHK$8,256,686,585JPMorgan Chase & Co, Private Banking and Investment Banking InvestmentsCompany102,577,861HK$80.49
06 Jan 22BuyHK$9,535,628J.P. Morgan Asset Management, Inc.Company127,046HK$75.06
06 Jan 22BuyHK$244,459JPMorgan Chase & Co, Private Banking and Investment Banking InvestmentsCompany3,257HK$75.06
06 Jan 22BuyHK$262,040,788JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany3,491,247HK$75.06
06 Jan 22SellHK$6,717,557J.P. Morgan Asset Management, Inc.Company89,500HK$75.06
06 Jan 22SellHK$75,057JPMorgan Chase & Co, Private Banking and Investment Banking InvestmentsCompany1,000HK$75.06
05 Jan 22BuyHK$61,622,433J.P. Morgan Asset Management, Inc.Company780,016HK$79.00
05 Jan 22BuyHK$4,068,577JPMorgan Chase & Co, Private Banking and Investment Banking InvestmentsCompany51,500HK$79.00
05 Jan 22SellHK$169,744,200JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany2,148,620HK$79.00
04 Jan 22BuyHK$227,231,652J.P. Morgan Asset Management, Inc.Company2,791,290HK$81.41
20 Dec 21SellHK$664,289,319J.P. Morgan Asset Management, Inc.Company7,775,231HK$85.44
16 Dec 21BuyHK$21,347,449Zhisheng ChenIndividual250,000HK$85.39
14 Dec 21BuyHK$199,172,305J.P. Morgan Asset Management, Inc.Company2,023,087HK$98.45
10 Dec 21SellHK$68,082,221J.P. Morgan Asset Management, Inc.Company677,862HK$100.44
06 Dec 21BuyHK$149,898,974J.P. Morgan Asset Management, Inc.Company1,552,040HK$96.58
09 Nov 21BuyHK$20,440,260Zhisheng ChenIndividual200,000HK$102.20
04 Nov 21BuyHK$38,658,450Zhisheng ChenIndividual370,000HK$104.48
25 Oct 21BuyHK$232,448,813J.P. Morgan Asset Management, Inc.Company1,980,403HK$117.37
19 Oct 21SellHK$131,989,656BlackRock, Inc.Company1,195,500HK$110.41

Ownership Breakdown

What is the ownership structure of 2269?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders12,768,8050.3%
Private Companies640,191,13315.0%
General Public1,666,655,78539.1%
Institutions1,946,197,29845.6%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 25 shareholders own 49.46% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
15.01%
Wuxi Biologics Holdings Limited
640,191,133CN¥30.9b-1.55%no data
7.09%
Capital Research and Management Company
302,577,937CN¥14.6b2.34%0.13%
5.98%
BlackRock, Inc.
254,953,394CN¥12.3b2.31%0.04%
3.82%
J.P. Morgan Asset Management, Inc.
163,027,712CN¥7.9b-4.56%0.19%
3.36%
The Vanguard Group, Inc.
143,501,667CN¥6.9b1.59%0.02%
1.89%
Invesco Ltd.
80,639,520CN¥3.9b-0.2%0.17%
1.27%
FMR LLC
53,996,359CN¥2.6b-1.49%0.03%
1.22%
Baillie Gifford & Co.
52,143,134CN¥2.5b0.05%0.16%
1.05%
State Street Global Advisors, Inc.
44,908,072CN¥2.2b8.52%0.02%
1.03%
Norges Bank Investment Management
43,949,161CN¥2.1b0%0.04%
0.95%
E Fund Management Co., Ltd.
40,566,000CN¥2.0b2012.81%0.42%
0.9%
Fidelity International Ltd
38,231,052CN¥1.8b0%0.13%
0.68%
abrdn plc
29,074,930CN¥1.4b-0.05%0.19%
0.64%
T. Rowe Price Group, Inc.
27,374,500CN¥1.3b-4.35%0.02%
0.62%
Amundi Asset Management
26,560,781CN¥1.3b32.49%0.05%
0.6%
Jennison Associates LLC
25,786,524CN¥1.2b967.57%0.14%
0.55%
China Universal Asset Management Company Ltd.
23,282,979CN¥1.1b0%0.5%
0.53%
UBS Asset Management
22,459,969CN¥1.1b1.94%0.03%
0.44%
Carmignac Gestion S.A.
18,657,829CN¥901.2m-10.1%1.12%
0.33%
Harding Loevner LP
13,921,495CN¥672.4m-5.98%0.25%
0.32%
Geode Capital Management, LLC
13,445,180CN¥649.4m2.01%0.01%
0.31%
Harvest Fund Management Co., Ltd.
13,172,000CN¥636.2m0.92%0.29%
0.3%
Hang Seng Investment Management Limited
12,648,701CN¥610.9m-6.41%0.98%
0.29%
Zhisheng Chen
12,583,966CN¥607.8m2.7%no data
0.29%
JPMorgan Chase & Co, Brokerage and Securities Investments
12,402,160CN¥599.0m99.71%0.08%

Company Information

WuXi Biologics (Cayman) Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: WuXi Biologics (Cayman) Inc.
  • Ticker: 2269
  • Exchange: SEHK
  • Founded: 2014
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: HK$206.039b
  • Shares outstanding: 4.27b
  • Website: https://www.wuxibiologics.com

Number of Employees


Location

  • WuXi Biologics (Cayman) Inc.
  • No. 108, Meiliang Road
  • Mashan
  • Wuxi
  • Jiangsu Province
  • 214092
  • China


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
2269SEHK (The Stock Exchange of Hong Kong Ltd.)YesOrdinary SharesHKHKDJun 2017
1FW2DB (Deutsche Boerse AG)YesOrdinary SharesDEEURJun 2017
2269SHSC (Stock Exchange of Hong Kong Limited - Shanghai - Hong Kong Stock Connect)YesOrdinary SharesHKHKDJun 2017
WXIB.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDJun 2017
2269SZSC (The Stock Exchange of Hong Kong - Shenzhen - Hong Kong Stock Connect)YesOrdinary SharesHKHKDJun 2017
2269 NBMV (Bolsa Mexicana de Valores)YesOrdinary SharesMXMXNJun 2017
WXXW.YOTCPK (Pink Sheets LLC)UNSPON ADR EACH REPR 2 ORD SHSUSUSDSep 2017
1FW1DB (Deutsche Boerse AG)UNSPON ADR EACH REPR 2 ORD SHSDEEURSep 2017

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/10/03 00:00
End of Day Share Price2022/10/03 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.